Compositions for targeting receptor for advanced glycation end-products (RAGE) in a chronic inflammatory condition
AssigneeSami-Sabinsa Group Limited
InventorsMuhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
Life of this patent
Estimating the term…
Abstract
The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises β-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.
Claims22
A method for inhibiting Receptor for Advanced Glycation End products (RAGE) expression in a subject with chronic inflammatory condition, comprising:
- (a) identifying said subject with the chronic inflammatory condition;
- b) administering to said subject with a composition comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w and β-amyrin palmitate (BAP).
A method of treating chronic inflammatory condition in a subject, comprising:
- (a) identifying said subject, b) administering said subject with a composition comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w and β-amyrin palmitate (BAP).
Dependencies are inferred from the claim text.